Standard immunosuppressive therapy of immune-mediated glomerular diseases

Autoimmunity Reviews

Volumn 12, Issue 8, 2013, Pages 848-853

  Pani, Antonello ^a  

^a BROTZU HOSPITAL   (Italy)

Author keywords

ANCA associated vasculitis; Glomerulonephritis; Immunosuppressive therapy; Nephrotic syndrome

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; INTERLEUKIN 2; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ANCA ASSOCIATED VASCULITIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE NECROSIS; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CD4+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; COMORBIDITY; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; CUSHING SYNDROME; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GLOMERULOPATHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE MEDIATED INJURY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY BIOPSY; KIDNEY FUNCTION; LIVER TOXICITY; LYMPHOCYTE FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; MOOD DISORDER; MYOPATHY; OBESITY; OSTEOPOROSIS; PEPTIC ULCER; PLASMAPHERESIS; PROTEINURIA; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP DISORDER; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; WEIGHT GAIN;

GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; NEPHROSIS, LIPOID; STEROIDS;

EID: 84878618705     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.11.012     Document Type: Review

References (70)

1. Renal Data System U.S. USRDS 2009 annual data report. Atlas of chronic kidney disease and end-stage renal disease in the United States 2009, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda,MD.
2. Canadian Institute for Health Information Annual report-treatment of end-stage organ failure in Canada, 1997 to 2006 2008, Author, Ottawa, ON.
3. Canadian Institute of Health Information Treatment of end-stage organ failure in Canada, 1995 to 2004. 2006 Annual report of the Canadian Organ Replacement Registry Ottawa 2007.
4. ERA-EDTA Registry ERA-EDTA registry annual report 2007.
5. Prakash S., Kanjanabuch T., Austin P.C., et al. Continental variations in IgA nephropathy among Asians. Clin Nephrol 2008, 70:377-384.
6. Youinou P., Hillion S., Jamin C., Pers J.O., Saraux A., Renaudineau Y.B. Lymphocytes on the front line of autoimmunity. Autoimmun Rev Mar 2006, 5(3):215-221.
7. Segelmark M., Hellmark T. Autoimmune kidney disease. Autoimmun Rev 2010, 9:A366-A371.
8. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010 Mar, 9(5):A259-A266.
9. Ponticelli C. Glucocorticoids and immunomodulating agents. Treatment of primary glomerulonephritis 2009, 47-126. (New York). 2nd ed. C. Ponticelli, R.J. Glassock (Eds.).
10. Cattran D.C., Reich H.N. Overview of therapy for glomerular disease. Philadelphia 2011, 1278-1296. 9th ed. M.W. Taal, G.M. Chertow, P.A. Marsden, K. Skorecki, A.S.L. Yu, B.M. Brenner (Eds.).
11. Barabas A.Z., Cole C.D., Graeff R.M., Lafreniere R., Weir D.M. The role of autoimmunologists in investigating and treating autoimmune disorders. Autoimmun Rev 2011 Jan, 10(3):166-170.
12. Murdaca G., Colombo B.M., Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011, 11(1):56-60.
13. Díaz-Lagares C., Croca S., Sangle S., Vital E.M., Catapano F., Martínez Berriotxoa A., et al. UK BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev Mar 2012, 11(5):357-364.
14. Senolt L., Vencovsky J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9(2):102-107.
15. Haas M., Spargo B.H., Coventry S. Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study. Am J Kidney Dis 1995, 26:740-750.
16. Ponticelli C., Passerini P. Treatment of the nephrotic syndrome associated with primary glomerulonephritis. Kidney Int 1994, 46(3):595-604.
17. Iseki K., Ikemiya Y., Iseki C., Takishita S. Proteinuria and the risk of developing end stage renal disease. Kidney Int 2003, 63:1468-1474.
18. Ruggenenti P., Perna A., Mosconi L., Pisoni R., Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998, 53(5):1209-1216.
19. Vincent J.L., Dubois M.J., Navickis R.J., Wilkes M.M. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Am Surg 2003, 237:319-334.
20. Bellomo R., Atkins R.C. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?. Nephron 1993, 63:249-254.
21. Kerlin B.A., Ayoob R., Smoyer W.E. Epidemiology and pathophisiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Nephrol 2012, 7:513-520.
22. Lionaki S., Derebail V.K., Hogan S.L., Barbour S., Lee T., Hladunnewick M., et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Nephrol 2012, 7:43-51.
23. Ordonez J.D., Hiatt R.A., Killebrew E.J., Fireman B.H. The increased risk of coronary heart disease associated with nephritic syndrome. Kidney Int 1993, 44:638-642.
24. Eddy A., Sumons J.M. Nephrotic syndrome in childhood. Lancet 2003, 362:629-639.
25. Tarshish P., Tobin J.N., Bernstein J., Edelman C.M. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997, 8(5):769.
26. Hodson E.M., Craig J.C. Therapies for steroid-resistant nephrotic syndrome. Pediatr Nephrol 2008, 23:1391-1394.
27. Cattran D.C., Alexopoulos E., Eeering P., Hoyer P.F., Johuston A., Merier A., et al. Cyclosporin in idiopatic syndrome. Workshop recommendations. Kidney Int 2007, 72:1429-1447.
28. Coppo R., Ponticelli C. Minimal change nephropathy. Treatment of primary glomerulonephritis 2009, 179-213. New York. 2nd ed. C. Ponticelli, R.J. Glassock (Eds.).
29. Ponticelli C., Villa M., Banfi G., Cesana B., Pozzi C., Pani A., et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?. Am J Kidney Dis 1999, 34:618-625.
30. Korbet S.M. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002, 62:2301-2310.
31. Ponticelli C., Passerini P. The place of cyclosporine in the management of primary nephrotic syndrome. BioDrugs 1999, 12:327-341.
32. Cattran D.C., Appel G.B., Herbert L.A., Hunsicker L.G., Pohl M.A., Hoy W.E., et al. A randomized trial of cyclosporine in patients with steroid resistant focal glomerulosclerosis. Kidney Int 1999, 56:2220-2226.
33. Appel GB, Cattran DC. Treatment of primary focal segmental glomerulosclerosis. (UptoDate 2011 ott 20).
34. Migliorini P., Pratesi F., Bongiorni F., Moscato S., Scavuzzo M., Bombardieri S. The targets of nephritogenic antibodies in systemic autoimmune disorders. Autoimmun Rev 2002, 1(3):168-173.
35. Barabas A.Z., Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 2005 Nov, 4(8):565-570.
36. Debiec H., Guigonis V., Mongenot B., Decobert F., Haymann J.P., Bensman A., et al. Antenatal membranous glomerulonephritis due to antineutral endopeptidose antibodies. N Engl J Med 2002, 346:2053-2060.
37. LH Js Beck, Bonegio R.G., Lambeau G., Beck D.M., Powell D.W., Cummins T.D., et al. M-type phropholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
38. Ponticelli C., Zucchelli P., Passerini P., Cagnoli L., Cesana B., Pozzi C., et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989, 320(1):8-13.
39. Ponticelli C., Zucchelli P., Passerini P., Cesana B., Locatelli F., Pasquali S., et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995, 48:1600-1604.
40. Ponticelli C., Altieri P., Scolari F., Passerini P., Roccatello D., Cesana B., et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998, 9:444-450.
41. Koyana H., Wada T., Nishizawa Y., Iwanaga T., Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977, 39:1403-1409.
42. Cattran D.C., Appel G.B., Herbert L.A., Hunsicker L.G., Pohl M.A., Hoi W.E., et al. North America Nephrotic Syndrome study Group: cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001, 59:1484-1490.
43. Praga M., Barrio V., Juerez G.F., Luno J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007, 71:924-930.
44. Falk R.J., Jennette J.C. ANCA disease: where is the field heading?. J Am Soc Nephrol 2010, 21:745-752.
45. Kallenberg C.G., Tadema H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to "autoimmunity and infection". Autoimmun Rev 2008 Oct, 8(1):29-32.
46. Cameron J.S. Renal vasculitis. Pediatr Nephrol 1988, 2(4):490-497.
47. Jones R.B., Teravaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
48. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
49. Fauci A.S., Katz P., Haynes B.F., Wolf S.M. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1997, 301:235-238.
50. Serra A., Cameron J.S., Turner R., Hartley B., Ogg C.S., Neil G.H., et al. Vasculitis affecting the kidney: presentation, histopathology and long term outcome. Q J of Med 1984, 210:181-207.
51. Balow J.E. Renal vasculities. Curr Opin Nephrol Hypertens 1983, 2(2):231-237.
52. Villiger P.M., Guillevin L. Microscopic polyangiitis: clinical presentation. Autoimmun Rev 2010, 9:812-819.
53. Nachman P.H., Hogan S.L., Jennette J.C., Falk R.J. Treatment response and relapse in antineutrophil cytoplasmatic auto-antibody-associated microscopic polyangitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:33-39.
54. Fervenza F.C. Rituximab in ANCA-associated vasculitis: fad or fact?. Clin Pract 2011, 118:c182-c188.
55. Cupps T.R., Edgar L.C., Fauci A.S. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982, 128(6):2453-2457.
56. Stevenson H.C., Fauci A.S. Activation of human B lymphocytes XII. Differential effects of in vitro cyclophosphamide on human lymphocyte sub populations involved in B-cell activation. Immunology 1980, 39(3):391-397.
57. Zhu L.P., Cupps T.R., Whalen G., Fauci A.S. Selective effects of cyclophosphamide therapy on activation, proliferation and differentiation of human B cells. J Clin Invest 1987, 79(4):1082-1090.
58. Mukhtyar C., Flossmann O., Hellmich B., Beacon P., Cid M., Cohen-Tervaert J.W., et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008, 67(7):1004-1010.
59. Zimmermann R., Radhakrishman J., Valeri A., Appel G. Advances in the treatment of lupus nephritis. Ann Rev Med 2001, 52:63-78.
60. Schönenberger E., Ehrich J.H., Haller H., Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011, 26(1):18-24.
61. Fauci A.S., Dale D.C., Balow J.E. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976, 84(3):304-315.
62. Rinehart J.J., Sagone A.L., Balcerzak S.P., Ackerman G.A., LoBuglio A.F. Effects of corticosteroid therapy on human monocyte function. N Engl J Med 1975, 292(5):236-241.
63. Settipane G.A., Pudupakkam R.K., McGowan J.H. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978, 62(3):162-166.
64. Zen M., Canova M., Campana C., Bettio S., Nalotto L., Rampudda M., et al. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011 Apr, 10(6):305-310.
65. Fan P.T., Yu D.T., Targoff C., Bluestone R. Effect of corticosteroids on the human immune response. Suppression of mitogen-induced lymphocyte proliferation by "pulse" methylprednisolone. Transplantation 1978, 26(4):266-267.
66. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11(6):954-963.
67. Cutolo M., Seriolo B., Pizzorni C., Secchi M.E., Soldano S., Paolino S., et al. Use of glucocorticoids and risk of infections. Autoimmun Rev 2008, 8(2):153-155.
68. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids. NEJM 2005, 353(16):1711-1723.
69. Latta K., Von Schnakenburg C., Ehrich J.H. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001, 16:271-282.
70. Manger K., Wildt L., Kalden J.R., Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2006 Apr, 5(4):269-272.